With a market capitalization (market cap) of $1.64B — a measure of how much the company is worth — Bicara Therapeutics Inc. Common Stock is the 2244th most valuable company in Healthcare as of August 18, 2026. Shares trade at $24.92, down +0.08% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Visit websiteAs of August 18, 2026, Bicara Therapeutics Inc. Common Stock (BCAX) is worth $1.64B — this is its market capitalization, the total value of all its outstanding shares.
Bicara Therapeutics Inc. Common Stock’s market cap is $1.64B, which ranks it #2244 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Bicara Therapeutics Inc. Common Stock (BCAX) shares trade at $24.92, down 0.08% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025